WHIPPANY, N.J., April 18, 2016 /PRNewswire/ -- Bayer Corporation announced today the appointment of Paul Capelli as Vice President of Communications for Bayer Consumer Health.
Capelli, who starts on April 18, comes to Bayer after five years as Vice President of Corporate Communications at QVC, Inc. Capelli will be responsible for internal & external communications for Bayer's Consumer Health Division. He will report to Raymond F. Kerins, Jr., SVP and head of U.S. Communications, Government Relations and Policy and will serve on the U.S. communications, government relations and policy leadership team.
"We are excited to have someone of Paul's experience and professionalism join the Bayer team. Paul knows this industry well and has all the skills necessary to push Bayer's reputation to even greater heights," Kerins said.
Bayer's Consumer Health Division is made up of some of the most iconic brands in the world such as Bayer ® Aspirin, Claritin®, Aleve®, Coppertone® and Dr. Scholl's®. After acquiring Merck's OTC business in 2014, Bayer became one of the largest consumer health businesses in North America and the world.
Capelli has spent more than a decade in consumer retail communications, most recently at QVC where he led a team that won the 2015 PRSA Silver Anvil Award for best in-house campaign, and at Staples. Capelli also spent time at CNBC, Amazon.com and Ketchum in various communications and public relations roles.
Capelli has served on the A.W. Page Society Board of Trustees, Miami PRSA and Advertising Federation Boards of Directors. He is a graduate of Rowan University in Glassboro, N.J.
About Bayer Corporation
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their lives. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer Corporation